Multi-Pathway Hair Enhancement
Three complementary active families spanning six distinct mechanisms: diaminopyrimidine N-oxide salts, cosmetic peptides, and prostaglandin analogs. Evidence-graded, literature-cited, and manufactured in the US.
3 Active Families
N-oxides, peptides, prostaglandins
6 Mechanism Pathways
Multi-target approach
Evidence Graded
Confidence-rated claims
US Manufactured
Fairfield, NJ
Where These Actives Fit
Comparative Positioning
Mironova offers both prostaglandin and non-prostaglandin pathways for hair enhancement. Below is where our N-oxide and peptide actives offer specific advantages — and where they differ from established options.
Prostaglandin-Free Formulation
Hair growth formulations without regulatory exposure to prostaglandin analog restrictions
Prostaglandin analogs (bimatoprost, IPCP, etc.)
EU SCCS/1680/25 concludes PG analogs “cannot be considered safe” for cosmetic lash/brow growth. Health Canada prohibits PGs in cosmetics. Periocular risks (iris pigmentation, PAP) are well documented.
Non-prostaglandin mechanism that does not share the pharmacological pathways associated with iris pigmentation or periorbital fat changes. Mironova offers both PG and non-PG pathways — this is the non-PG option for markets or brands requiring it.,
Water-Soluble Hair Active
Aqueous formulations without co-solvents or hydroalcoholic vehicles
Minoxidil (free base)
Minoxidil base has an aqueous solubility of approximately 2.2 mg/mL at 25 °C , requiring propylene glycol/ethanol vehicles that can cause scalp irritation and dryness.
OTZ salt forms dissolve freely in water, enabling aqueous serums, tonics, and shampoo integration without co-solvents. Avoids the ethanol co-solvent requirement associated with some PG formulations.
Collagen Modulation Approach
Targeting perifollicular collagen rigidification in androgenetic alopecia
No standard cosmetic active targets this pathway
Perifollicular fibrosis is documented in AGA but is not addressed by most hair growth actives, which focus on vasodilation or growth factor signaling.
DPO modulates lysyl hydroxylase mRNA expression in vitro, supporting a collagen maturation pathway relevant to perifollicular tissue biology. Based on Mahé et al. (1996) structure–activity data., ,
Cosmetic-Grade Claims
Products positioned as cosmetics rather than OTC drugs
Minoxidil (OTC)
Minoxidil is classified as an OTC product. Any product containing minoxidil must follow corresponding regulations and labeling. Restoration claims require specific approval.
PDPO and DPO are cosmetic ingredients (INCI-registered). Cosmetic claim sets (“fuller-looking hair,” “reduces visible shedding”) are available without OTC pathway. Claims must remain appearance-focused.
Multi-Target Strategy
Addressing multiple pathophysiological axes of hair loss simultaneously
Single-mechanism actives (caffeine, peptide blends)
AGA is multifactorial (androgen signaling, inflammation, fibrosis, vascular insufficiency). Single-mechanism actives address only one axis.
Three distinct pathways: follicular signaling (PDPO, diaminopyrimidine N-oxide class), collagen maturation modulation (DPO), and cysteine/GSH support (OTZ). Mechanistic complementarity is plausible, though combination synergy has not been demonstrated experimentally., ,
Formulation Flexibility
Integration into diverse cosmetic vehicle systems
Hydroalcoholic solutions
Many hair actives require ethanol/propylene glycol vehicles (minoxidil: ~2.2 mg/mL aqueous solubility ), limiting use in gentle or rinse-off formulations and causing scalp dryness.
True water solubility enables clear aqueous serums, scalp tonics, shampoos, conditioners, and leave-on sprays. No co-solvents needed. Compatible with most aqueous cosmetic systems at pH 4.0–6.5.
Lash/Brow Peptide Actives
Cosmetic peptide ingredients for eyelash and eyebrow enhancement serums
Redensyl, Capixyl (Acetyl Tetrapeptide-3), generic peptide blends
Many marketed lash peptide blends lack ingredient-specific data. Capixyl data cannot be attributed to Biotinoyl Tripeptide-1 (different peptide). Evidence quality varies widely across suppliers.
Mironova supplies four cosmetic peptides with clearly graded evidence levels: Biotinoyl Tripeptide-1 (strongest evidence, supplier ex vivo data) and three Myristoyl lipopeptides for keratin support and multi-peptide formulations. Evidence grades are disclosed transparently.,
Matrikine / ECM Support
Targeting extracellular matrix remodeling in the follicular environment
GHK-Cu (copper peptide), Procapil (3-ingredient complex)
GHK-Cu is a well-characterized ECM modulator, but its copper coordination raises formulation complexity and stability challenges. Procapil clinical data tests the full complex, not the peptide component alone.
Biotinoyl Tripeptide-1 preserves laminin-5 and collagen IV in the dermal papilla and root sheath (supplier ex vivo data). Copper-free GHK conjugate simplifies formulation. Follicular localization demonstrated by immunolabeling.,
Multi-Family Portfolio Formulation
Combining small-molecule actives and peptides in a single product for complementary mechanisms
Single-ingredient serums or multi-brand ingredient sourcing
Sourcing small molecules and peptides from separate suppliers adds vendor qualification burden, complicates supply chain, and limits formulation support.
Single-source portfolio: N-oxide actives (0.2–1.5% w/w) for channel-opening and collagen modulation, OTZ counterion for antioxidant support, plus cosmetic peptides (1–50 ppm) for ECM and keratin support. Both families are water-soluble with overlapping pH stability ranges.
Mechanism of Action
Six Mechanistic Pathways Across Three Active Families
Each pathway is presented with an evidence confidence rating. We distinguish between what the literature directly supports and what remains a plausible hypothesis.
Diaminopyrimidine N-Oxide Salts
K₊ATP channel biology, collagen modulation, and cysteine/GSH support via OTZ salt forms.
PDPO shares the 2,4-diaminopyrimidine N-oxide pharmacophore with minoxidil. K₊ATP channel biology is well established for the compound class, though PDPO-specific pharmacological data remains limited.
- PDPO is a structural analog of minoxidil, differing by a pyrrolidine ring (vs piperidinyl in minoxidil) at the C6 position.
- Human hair follicles express two forms of ATP-sensitive potassium channels, with one form responsive to minoxidil-class openers .
- Minoxidil’s follicular effects include VEGF upregulation , β-catenin pathway activation , and adenosine-mediated signaling through SUR2B in dermal papilla cells .
- PDPO’s specific K₊ATP channel activity, EC₅₀, and subtype selectivity have not been characterized in published peer-reviewed studies.
Evidence Assessment
Strong evidence for the compound class (minoxidil); limited standalone evidence for PDPO specifically. Structural analogy supports a plausible hypothesis, not a confirmed mechanism.
Evidence Gaps
- • No published PDPO-specific K₊ATP electrophysiology or EC₅₀ data
- • Wnt/β-catenin activation not demonstrated for PDPO (only for minoxidil)
- • TGF-β1 downregulation not demonstrated for PDPO
- • No PDPO monotherapy clinical trials identified
Cosmetic Peptides
GHK matrikine signaling and myristoylated lipopeptides for ECM remodeling and keratin support.
Prostaglandin Analogs
FP receptor-mediated anagen prolongation with FDA-approved clinical precedent.
Published Evidence
What the Literature Supports
The information on this page references published research where available. We rate each finding by evidence quality and explicitly note limitations — because transparent science is better science.
Lysyl Hydroxylase mRNA Modulation by Aminexil
DPO (aminexil) retains strong inhibition of lysyl hydroxylase mRNA expression despite lacking the C6 substituent present in minoxidil
Using RT-PCR as a sensitive readout in a structure–activity framework, Mahé et al. demonstrated that 2,4-diaminopyrimidine-3-oxide (aminexil) modulates lysyl hydroxylase gene expression in vitro, targeting the collagen maturation pathway rather than the vasodilatory K₊ATP channel arm.
In vitro study using RT-PCR; does not establish LOX enzyme kinetics (Ki/IC₅₀) and has not been replicated with quantitative protein-level measurements.
Two K₊ATP Channel Forms in Human Hair Follicles
Human hair follicles contain two distinct forms of ATP-sensitive potassium channels, only one of which responds to minoxidil-class openers
Shorter et al. identified K₊ATP channel expression in human hair follicle tissue and demonstrated differential sensitivity to minoxidil, establishing that channel pharmacology is relevant to follicular biology.
Study characterized channels in follicle tissue broadly; compartment-specific mapping (dermal papilla vs ORS vs bulge) is not fully resolved. PDPO was not tested.
Multi-Ingredient Topical in Early Female Pattern Hair Loss
A multi-ingredient formulation including PDPO showed positive hair parameters in women with early FPHL
Draelos et al. evaluated Spectral.DNC-N® containing PDPO alongside multiple other actives. Participants showed improvements in hair count and thickness measures over the treatment period.
Multi-ingredient design makes it impossible to attribute effects to PDPO specifically. No placebo-controlled PDPO monotherapy data has been published.
Perifollicular Fibrosis and Inflammation in AGA
Collagenous sheath thickening and inflammatory infiltrates are documented around miniaturizing follicles in androgenetic alopecia
Multiple histological studies (Jaworsky 1992, Whiting 1993, Umar 2026) demonstrate perifollicular inflammation and fibrotic remodeling in AGA scalps. Contemporary reviews frame fibrosis as a plausible modifiable axis, though whether it is a primary cause or secondary consequence of miniaturization remains debated.
Causal direction is uncertain — fibrosis may be consequence rather than driver. However, targeting this axis remains a rational strategy given the histological evidence.
Minoxidil Upregulates VEGF in Dermal Papilla Cells
Minoxidil increases VEGF expression in dermal papilla cells, supporting vascular and growth factor mechanisms for the diaminopyrimidine N-oxide class
Lachgar et al. demonstrated VEGF mRNA upregulation in cultured human dermal papilla cells treated with minoxidil, providing a molecular basis for the vascular component of minoxidil-class hair growth effects.
Demonstrated for minoxidil specifically. PDPO has not been tested in equivalent assays, so VEGF upregulation cannot be attributed to PDPO by analogy alone.
OTZ as Intracellular Cysteine/Glutathione Prodrug
OTZ is converted to cysteine by 5-oxoprolinase, supporting glutathione biosynthesis across multiple tissue types
Isotopic tracer studies and clinical investigations confirm that OTZ is intracellularly converted to L-cysteine, which feeds into glutathione synthesis. This has been demonstrated in systemic contexts including clinical trials and ex vivo tissue models.
All published data is from systemic administration or non-follicular tissues. No topical scalp or hair follicle studies for OTZ have been published. Follicular 5-oxoprolinase expression has not been confirmed.
TGF-β1 as Androgen-Inducible Catagen Mediator
Androgen-induced TGF-β1 from dermal papilla cells suppresses epithelial growth, establishing TGF-β as a key catagen-promoting signal in AGA
Inui et al. identified TGF-β1 as a key androgen-inducible mediator in AGA, with ROS involvement in the signaling cascade (Shin et al. 2013). This provides the mechanistic rationale for why antioxidant support (via OTZ/GSH) may be relevant to the AGA microenvironment.
While TGF-β biology in AGA is well established, no published evidence shows that PDPO or OTZ specifically modulate TGF-β1 in follicular tissue.
GHK Modulates Over 4,000 Human Genes via Connectivity Map
Connectivity Map data indicates GHK at 1 µM modulates over 4,000 human genes, including ECM synthesis, growth factors (VEGF, bFGF), anti-inflammatory pathways, and stem cell maintenance
Pickart & Margolina (2018) analyzed Connectivity Map data showing GHK modulates 2,687 upregulated and 1,513 downregulated genes at ≥50% change. Campbell et al. (2012) independently validated CMap predictions, confirming GHK at 10 nM reverses disease gene signatures in primary human fibroblasts.
CMap data comprises only three expression profiles from two cancer cell lines (PC3, MCF7), making it statistically underpowered by modern standards. Independent validation (Campbell 2012) substantially bolsters confidence but used lung fibroblasts, not follicular cells.
Tripeptide-Copper Complex Stimulates Hair Follicle Growth Ex Vivo
AHK-Cu (Ala-His-Lys-Cu, a GHK analog) stimulates human hair follicle elongation and dermal papilla cell proliferation while suppressing apoptosis
Pyo et al. (2007) demonstrated that AHK-Cu at 10⁻¹² to 10⁻⁹ M stimulated ex vivo human hair shaft elongation, increased DPC proliferation, elevated Bcl-2/Bax ratio, and reduced cleaved caspase-3 by 42.7% and PARP by 77.5%.
This study used AHK-Cu (Ala-His-Lys), not GHK-Cu (Gly-His-Lys). While structurally related, they are distinct peptides. Marketing literature that cites this study as evidence for GHK-Cu or Biotinoyl Tripeptide-1 is technically inaccurate.
Biotinoyl Tripeptide-1 Stimulates Ex Vivo Follicular Growth
Biotinoyl Tripeptide-1 at 2 ppm increased hair follicle growth by 58% ex vivo, comparable to minoxidil; at 5 ppm, growth was 121% greater than controls
Sederma’s contract research (BIO-EC) cultured human hair follicle explants for 14 days with Biotinoyl Tripeptide-1 alone. Ki67 immunostaining confirmed maintained keratinocyte proliferation. Immunofluorescence showed the peptide preserved basement membrane proteins (laminin-5, collagen IV).
Supplier-generated data that has not been published in a peer-reviewed journal or independently replicated. The ex vivo culture model does not account for the complex hormonal, vascular, and immune environment of the human scalp.
GHK + 5-ALA RCT Shows Hair Count Increase in AGA
The only controlled clinical trial for a GHK-containing formulation showed +52 to +72 hairs vs +10 for placebo over 6 months in 45 men with AGA
Lee et al. (2016) conducted a double-blind, placebo-controlled RCT using ALAVAX (5-aminolevulinic acid + free GHK without copper) in 45 men with androgenetic alopecia over 6 months. Zero adverse events reported.
GHK was combined with 5-ALA; the individual contribution of GHK cannot be isolated. The study used free GHK (not GHK-Cu or Biotinoyl Tripeptide-1), so results may not directly apply to other molecular forms.
CIR Expert Panel: Tripeptide-1 Safe in Cosmetics
The independent CIR Expert Panel concluded that Tripeptide-1, Copper Tripeptide-1, and related derivatives are safe in cosmetics at current use concentrations
Johnson et al. (2018) reviewed acute oral toxicity (LD₅₀ >2,000 mg/kg), negative RIPT, minimal ocular irritation, and nonmutagenic Ames test results. Ong et al. (2016) showed GHK-Cu is non-cytotoxic and non-irritating while equivalent free copper salts induced toxicity markers.
The CIR assessment covers the peptide class broadly; it does not specifically evaluate the four myristoylated lipopeptides (Pentapeptide-17, Hexapeptide-16, Tetrapeptide-12) as individual ingredients.
Bimatoprost Phase III Trial for Eyelash Hypotrichosis
Bimatoprost 0.03% applied to the upper eyelid margin significantly increased eyelash length, thickness, and darkness versus vehicle in a pivotal Phase III trial
Smith et al. (2012) conducted a multicenter, double-blind, vehicle-controlled trial. Bimatoprost-treated subjects showed statistically significant improvements across all three primary endpoints (length, thickness, darkness) at 16 weeks, forming the basis for FDA approval of Latisse.
Trial was conducted for eyelash application only; scalp hair outcomes were not assessed. Periorbital adverse effects (conjunctival hyperemia, periorbital skin pigmentation) were documented in a subset of subjects.
Latanoprost RCT for Scalp Androgenetic Alopecia
Latanoprost 0.1% applied topically to AGA-affected scalp increased hair density versus placebo over 24 weeks — the first RCT evidence for a prostaglandin analog in scalp hair enhancement
Blume-Peytavi et al. (2012) conducted a randomized, double-blind, placebo-controlled pilot study. Latanoprost-treated areas showed significant increases in both terminal and vellus hair density compared to placebo-treated areas on the same scalp.
Small pilot study with limited sample size. Scalp-specific safety and long-term outcomes were not fully characterized. Regulatory classification of a PG analog for scalp use may differ from ophthalmic/cosmetic eyelash applications.
Formulation Guide
Formulation Guide
Practical guidance for formulating with N-oxide actives and cosmetic peptides. These are starting points — formulation-specific testing is always recommended.
Regulatory Context
Non-Prostaglandin Positioning
Mironova offers both prostaglandin analogs and non-prostaglandin actives. For formulators who need prostaglandin-free alternatives — whether due to regulatory requirements, brand positioning, or market access — these actives provide a different pathway.
European Union
Increasing PG restrictions
- SCCS/1680/25 (Feb 2026) concludes prostaglandin analogs MDN, IPCP, and DDDE “cannot be considered safe” in cosmetic products intended to promote eyelash/eyebrow growth.
- Diaminopyrimidine oxide (DPO) is listed in EU Annex III/93 with a maximum concentration of 1.5%.
- Products claiming to “stimulate hair growth” are assessed case-by-case for cosmetic vs medicinal classification.
Canada
PGs prohibited in cosmetics
- Health Canada’s Cosmetic Ingredient Hotlist prohibits prostaglandins, their salts, derivatives and analogues in cosmetic products.
- PDPO and DPO are not prostaglandin analogs and are not covered by this prohibition.
- Brands selling in Canada increasingly specify “prostaglandin-free” formulations.
United States
Claim-driven classification
- FDA classification depends on intended use, not ingredient identity. “Hair restoration” = medical claim. “Fuller-looking hair” = cosmetic claim.
- 21 CFR 310.527 addresses OTC hair grower/hair loss prevention claims — these lack GRASE status.
- MoCRA (2022) adds cosmetic safety substantiation requirements but does not change the medical/cosmetic claim boundary.
Claims Language Guide
Cosmetic claims must focus on appearance and maintenance, not treatment or disease modification.
Cosmetic-Safe Language
- Supports the appearance of fuller, thicker-looking hair
- Helps reduce visible shedding
- Supports a healthy scalp environment
- Improves hair manageability and body
- Helps maintain natural hair density
Avoid (Medical Claims)
- Restores hair
- Cures or treats medical conditions
- Reverses miniaturization
- Clinically validated to restore hair
- Prevents hair loss
Peptide Claims Discipline
MoCRA (2022) requires adequate substantiation for cosmetic product safety and claims. Mironova grades each peptide’s evidence level transparently. “Supports the appearance of” is the appropriate claim framework for all four peptides.
| Peptide | Strongest Evidence | Grade | Key Limitation |
|---|---|---|---|
| Biotinoyl Tripeptide-1 | Ex vivo follicle growth (+58–121%), laminin-5/collagen IV preservation, follicular localization | DEMONSTRATED (supplier) | No independent peer-reviewed replication; clinical data is for Procapil complex only |
| Myristoyl Pentapeptide-17 | In vitro keratin gene upregulation (KRT3, KRT19, lumican), supplier eyelash study | SUPPLIER DATA | Hair loss study (n=24) did not reach statistical significance; KRT31/KRT35 claims are unsupported |
| Myristoyl Hexapeptide-16 | Designed as companion to Pentapeptide-17; cationic lipopeptide class reasoning | CLASS EVIDENCE | No peptide-specific efficacy data published or available; thinnest evidence base of all four |
| Myristoyl Tetrapeptide-12 | Myristoyl tetrapeptide class shows ECM modulation via TGF-β/SMAD signaling | CLASS EVIDENCE | Published data is for different peptide sequences (mAAPV, mGLFW), not this specific KAKA sequence |
Grades: DEMONSTRATED = peptide-specific data exists (may be supplier-only). CLASS EVIDENCE = data from related compounds or peptide class. HYPOTHETICAL = mechanistically plausible, no direct data. See product pages for full evidence detail.
Product & Quality
Six Actives. One Quality Standard.
Two OTZ salt forms and four cosmetic peptides, all manufactured with full analytical characterization. Prostaglandin analogs are covered in our dedicated prostaglandin catalog.
Kopyrrol Aqua
PDPO·OTZ
PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE OXOTHIAZOLIDINECARBOXYLATE
≥98% (HPLC)
Freely soluble in water
3.0–4.0 (1.5% aqueous)
0.2–1.5% (w/w)
Diaminopyrimidine N-oxide class (follicular signaling hypothesis)
Kopexil Aqua
DPO·OTZ
DIAMINOPYRIMIDINE OXIDE OXOTHIAZOLIDINECARBOXYLATE
≥98% (HPLC)
Freely soluble in water
2.0–3.0 (1.5% aqueous)
0.2–1.5% (w/w)
Lysyl hydroxylase mRNA modulation (collagen maturation pathway)
Biotinoyl Tripeptide-1
Biotin-GHK
BIOTINOYL TRIPEPTIDE-1
≥95% (HPLC)
Freely soluble in water
4.5–7.5 (aqueous solution)
1–50 ppm (w/w)
GHK-class matrikine signaling (ECM remodeling in dermal papilla)
Myristoyl Pentapeptide-17
Myr-PP17
MYRISTOYL PENTAPEPTIDE-17
≥95% (HPLC)
Soluble in water and aqueous buffers
5.0–7.0 (aqueous solution)
1–10 ppm (w/w)
Keratin gene upregulation in follicular keratinocytes (supplier in vitro data)
Myristoyl Hexapeptide-16
Myr-HP16
MYRISTOYL HEXAPEPTIDE-16
≥95% (HPLC)
Soluble in water; slight warming may aid dissolution
5.0–7.0 (aqueous solution)
1–20 ppm (w/w)
Lipopeptide companion active for eyelash/brow and scalp serums (supplier data)
Myristoyl Tetrapeptide-12
Myr-TP12
MYRISTOYL TETRAPEPTIDE-12
≥95% (HPLC)
Soluble in water and aqueous buffers
4.5–7.5 (aqueous solution)
1–20 ppm (w/w)
Dermal papilla ECM remodeling (collagen IV, fibronectin upregulation; supplier data)
Manufacturing & Quality
US-Based Manufacturing
Produced at our Fairfield, NJ facility with full supply chain transparency.
Certificate of Analysis
Every batch ships with CoA including HPLC purity, identity confirmation, and moisture content.
Batch Consistency
Stoichiometry confirmed by HPLC and elemental analysis for each batch.
Custom Synthesis
Additional OTZ salt forms or custom diaminopyrimidine derivatives available on request.
Request a Sample
Evaluate Our Hair Enhancement Actives
Request evaluation samples from our full portfolio — N-oxide actives, cosmetic peptides, prostaglandin analogs, or any combination. Select multiple products to receive a combination evaluation kit.
Sample Quantities
5–25 g evaluation samples shipped within 1–2 weeks, with development and commercial scale available on request
Technical Documentation
CoA, formulation guidance, and use-level recommendations included with every sample shipment
Technical Support
Direct access to our chemistry team for formulation optimization, pH adjustment, and compatibility testing
References
Literature & Sources
Technical claims on this page are grounded in peer-reviewed literature and official regulatory sources. DOIs are provided where available. Evidence limitations are noted throughout.
Peer-Reviewed Literature
A Minoxidil-Related Compound Lacking a C6 Substitution Still Exhibits Strong Anti-Lysyl Hydroxylase Activity in vitro
Mahé YF, Buan B, Bernard BA
Skin Pharmacology
Aminexil (2,4-diaminopyrimidine-3-oxide / DPO) retains strong inhibition of lysyl hydroxylase mRNA expression in vitro, establishing the collagen maturation modulation mechanism for the compound class.
Minoxidil: Mechanisms of Action on Hair Growth
Messenger AG, Rundegren J
British Journal of Dermatology
Comprehensive review of minoxidil’s mechanisms including K₊ATP channel opening, VEGF upregulation, and direct follicular effects — providing the pharmacological benchmark for the diaminopyrimidine N-oxide compound class.
Human Hair Follicles Contain Two Forms of ATP-Sensitive Potassium Channels, Only One of Which Is Sensitive to Minoxidil
Shorter K, Farjo NP, Picksley SM, Randall VA
FASEB Journal
Two forms of K₊ATP channels exist in human hair follicles, with only one sensitive to minoxidil-class openers. Establishes that K₊ATP channel biology is relevant to human follicle pharmacology.
Minoxidil Activates β-Catenin Pathway in Human Dermal Papilla Cells: A Possible Explanation for Its Anagen Prolongation Effect
Kwack MH, Kang BM, Kim MK, Kim JC, Sung YK
Journal of Dermatological Science
Minoxidil activates β-catenin signaling in dermal papilla cells and prolongs anagen in a mouse model. Demonstrates Wnt pathway engagement for the minoxidil class — but this has not been shown for PDPO.
Effects of a New Topical Treatment Containing Several Hair Growth Promoters in Women with Early Female Pattern Hair Loss
Draelos ZD, et al.
Skin Appendage Disorders
Multi-ingredient topical (Spectral.DNC-N®) including PDPO showed positive hair parameters in early FPHL. Effects cannot be attributed to PDPO specifically due to multi-ingredient design.
Minoxidil Upregulates the Expression of Vascular Endothelial Growth Factor in Human Hair Dermal Papilla Cells
Lachgar S, Charveron M, Gall Y, Bonafé JL
British Journal of Dermatology
Minoxidil increases VEGF mRNA expression in cultured human dermal papilla cells, supporting a vascular/growth factor mechanism for the compound class.
Minoxidil-Induced Hair Growth Is Mediated by Adenosine in Cultured Dermal Papilla Cells: Possible Involvement of Sulfonylurea Receptor 2B as a Target of Minoxidil
Marubayashi A, Nakaya Y, Fukui K, et al.
Journal of Investigative Dermatology
SUR2B expression identified in dermal papilla cells. Minoxidil-induced hair growth may involve adenosine signaling through SUR2B, suggesting K₊ATP channel effects in follicles are indirect.
Characterization of Inflammatory Infiltrates in Male Pattern Alopecia: Implications for Pathogenesis
Jaworsky C, Kligman AM, Murphy GF
British Journal of Dermatology
Perifollicular inflammatory infiltrates are present in AGA scalps, establishing the histological basis for inflammation and fibrosis as contributing factors in pattern hair loss.
Identification of Androgen-Inducible TGF-β1 Derived from Dermal Papilla Cells as a Key Mediator in Androgenetic Alopecia
Inui S, Fukuzato Y, Nakajima T, Yoshikawa K, Itami S
Journal of Investigative Dermatology Symposium Proceedings
Androgen-inducible TGF-β1 from dermal papilla cells suppresses epithelial growth in AGA, identifying TGF-β signaling as a key therapeutic target.
Topical Products for Human Hair Regeneration: A Comparative Study of Hair Loss Topical Treatments Using a Rat Model
Yousef M, et al.
Annals of Dermatology
Comparative animal model study including aminexil commercial products vs minoxidil. Reports comparative efficacy in rat model but does not isolate DPO as a single active.
Induction of Transforming Growth Factor-β1 by Androgen Is Mediated by Reactive Oxygen Species in Hair Follicle Dermal Papilla Cells
Shin H, Yoo HG, Inui S, et al.
BMB Reports
ROS mediates androgen-induced TGF-β1 expression in dermal papilla cells, linking oxidative stress to catagen-promoting signals in AGA.
l-2-[¹³C]Oxothiazolidine-4-Carboxylic Acid: A Probe for Precursor Cysteine Availability
Fukagawa NK, Hercules E, Ajami AM
American Journal of Physiology — Endocrinology and Metabolism
Confirms the intracellular conversion of OTZ to cysteine via 5-oxoprolinase, establishing the biochemical pathway for GSH precursor activity.
Effect of the Cysteine Prodrug L-2-Oxothiazolidine-4-Carboxylic Acid on Oxidative Stress and Glutathione
Beegam S, Zaaba NE, Elzaki O, Yasin J, Ali BH, Nemmar A
Frontiers in Toxicology
Comprehensive review of OTZ as a cysteine/GSH prodrug across multiple biological contexts, supporting its antioxidant and cysteine-donor properties.
Diagnostic and Predictive Value of Horizontal Sections of Scalp Biopsy Specimens in Male Pattern Androgenetic Alopecia
Whiting DA
Journal of the American Academy of Dermatology
Horizontal scalp biopsy methodology for AGA diagnosis, demonstrating follicular miniaturization and perifollicular changes.
Perifollicular Inflammation and Fibrosis in Androgenetic Alopecia
Umar S, Tan BH, Shitabata PK
Clinical, Cosmetic and Investigational Dermatology
Contemporary evidence for perifollicular fibrosis and inflammation as factors in AGA progression, supporting research into collagen modulation strategies.
The Role of Fibrosis in Androgenetic Alopecia: Mechanisms and Implications
Li L, Chen Y, Lin M, Chen T, Xi Y, Fan Y, Ding X
Skin Appendage Disorders
Review framing perifollicular fibrosis as a modifiable axis in AGA, with collagen cross-linking pathways as potential intervention targets.
Isolation and Structural Identification of a Novel Minoxidil Analogue in an Illegal Dietary Supplement: Triaminodil
Cao Y, et al.
Food Additives & Contaminants: Part A
PDPO (triaminodil) identified as a structural analog of minoxidil in analytical chemistry context, confirming the 2,4-diaminopyrimidine N-oxide pharmacophore relationship.
2-Oxothiazolidine-4-Carboxylic Acid Inhibits Vascular Calcification via Induction of Glutathione Synthesis
Patel JJ, Bourne LE, Thakur S, Farrington K, Gorog DA, Orriss IR, Baydoun AR
Journal of Cellular Physiology
OTZ inhibits vascular calcification through GSH synthesis induction, providing additional evidence for the compound’s biological activity as a cysteine/GSH prodrug beyond the hair context.
Solubility of Minoxidil in Methanol, Ethanol, 1-Propanol, 2-Propanol, 1-Butanol, and Water from (278.15 to 333.15) K
Han JH, et al.
J. Chem. Eng. Data
Minoxidil aqueous solubility is approximately 2.2 mg/mL at 25 °C — classified as “slightly soluble.” Solubility in propylene glycol (~75 mg/mL) and ethanol (~29 mg/mL) explains the requirement for organic co-solvents in topical formulations.
Stimulation of Hepatic Glutathione Formation by Administration of L-2-Oxothiazolidine-4-Carboxylate, a 5-Oxo-L-Prolinase Substrate
Williamson JM, Meister A
Proc. Natl. Acad. Sci. USA
Foundational paper establishing OTZ as a substrate for 5-oxo-L-prolinase, yielding intracellular L-cysteine. OTZ administration to GSH-depleted mice restored normal hepatic glutathione levels. Described as “an intracellular delivery system for cysteine.”
Intracellular Cysteine Delivery System That Protects Against Toxicity by Promoting Glutathione Synthesis
Williamson JM, Boettcher B, Meister A
Proc. Natl. Acad. Sci. USA
OTZ protects against acetaminophen toxicity in mice by promoting glutathione synthesis. Establishes OTZ as a practical, non-toxic intracellular cysteine delivery system.
Sustained Effect of Two Antioxidants (Oxothiazolidine and δ-Tocopheryl Glucoside) for Immediate and Long-Term Sun Protection in a Sunscreen Emulsion
Jacques C, Bacqueville D, Jeanjean-Miquel C, Noize A, Nardou C, Tourette A, Bessou-Touya S, Duplan H
Int. J. Cosmetic Science
OTZ formulated in a sunscreen emulsion was rapidly and extensively absorbed through reconstructed human epidermis. Provides direct evidence for topical OTZ penetration and antioxidant activity in a cosmetic context.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A
International Journal of Molecular Sciences
Comprehensive review demonstrating that GHK modulates expression of over 4,000 human genes based on Connectivity Map data, including ECM remodeling, anti-inflammatory, and stem cell-related pathways relevant to follicular biology.
A Gene Expression Signature of Emphysema-Related Lung Destruction and Its Reversal by the Tripeptide GHK
Campbell JD, McDonough JE, Zeskind JE, et al.
Genome Medicine
Independent multi-institutional validation of GHK’s Connectivity Map gene expression predictions. Confirmed that GHK at 10 nM reverses disease-associated gene expression patterns in primary human fibroblasts, substantially bolstering confidence in CMap-derived claims.
The Effect of Tripeptide-Copper Complex on Human Hair Growth in vitro
Pyo HK, Yoo HG, Won CH, et al.
Archives of Pharmacal Research
Ex vivo study demonstrating that a tripeptide-copper complex (AHK-Cu, not GHK-Cu) stimulates human hair follicle elongation and dermal papilla cell proliferation while suppressing apoptosis (42.7% caspase-3 reduction, 77.5% PARP reduction). Note: frequently miscited as GHK-Cu evidence.
Efficacy and Safety of Topical 5-Aminolevulinic Acid Photodynamic Therapy and GHK Peptide for Androgenetic Alopecia
Lee WJ, Kim KH, et al.
Annals of Dermatology
Double-blind, placebo-controlled RCT in 45 men over 6 months. Hair counts increased by +52 to +72 hairs in treatment groups versus +10 for placebo (p<0.05). Limitation: GHK was combined with 5-ALA, so its individual contribution cannot be isolated.
Thermodynamically Stable Ionic Liquid Microemulsions Pioneer Pathways for Topical Delivery and Peptide Application
Liu T, et al.
Bioactive Materials
GHK-Cu delivered via ionic liquid microemulsion induced anagen in mice within 6 days versus 9 days for 5% minoxidil, with confirmed upregulation of VEGF, HGF, and Wnt/β-catenin signaling.
Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds
Ong KL, et al.
Scientific Reports
GHK-Cu showed no cytotoxicity and no elevation of irritancy biomarkers in HaCaT keratinocytes, while equivalent concentrations of free copper salts induced both cytotoxicity and irritancy markers — demonstrating that GHK complexation effectively quenches copper’s redox toxicity.
Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics
Johnson W, Bergfeld WF, Belsito DV, et al.
International Journal of Toxicology
CIR Expert Panel safety assessment concluding that Tripeptide-1, Copper Tripeptide-1, and related derivatives are “safe in cosmetics in the present practices of use and concentration.” Supporting data included negative RIPT, Ames test, and minimal irritation.
Eyelash Growth in Subjects Treated with Bimatoprost: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study
Smith S, Fagien S, Whitcup SM, et al.
Journal of the American Academy of Dermatology
Phase III trial (n=278) demonstrating bimatoprost 0.03% applied to the upper eyelid margin significantly increases eyelash length, thickness, and darkness versus vehicle (78.1% vs 18.4% responders at 16 weeks, P<.0001), forming the basis for FDA approval of Latisse.
Identification and Pharmacological Characterization of the Prostaglandin FP Receptor and FP Receptor Variant Complexes
Liang Y, Woodward DF, Guzman VM, Li C, Scott DF, Wang JW, Wheeler LA, Garst ME, Landsverk K, Sachs G, Bhatt K, Krauss AHP
British Journal of Pharmacology
Identifies and characterizes the prostaglandin FP receptor and FP receptor variant complexes, establishing the pharmacological basis for how prostaglandin F2α analogs mediate biological effects including hair follicle stimulation.
A Randomized Double-Blind Placebo-Controlled Pilot Study to Assess the Efficacy of a 24-Week Topical Treatment by Latanoprost 0.1% on Hair Growth and Pigmentation in Healthy Volunteers with Androgenetic Alopecia
Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N
Journal of the American Academy of Dermatology
Randomized, double-blind, placebo-controlled pilot study (n=16) showing latanoprost 0.1% applied topically to AGA-affected scalp significantly increased hair density versus baseline (P<.001) and placebo (P=.0004) over 24 weeks, providing early RCT evidence for a prostaglandin analog in scalp hair enhancement.
A Cross-Sectional Survey of the Association between Bilateral Topical Prostaglandin Analogue Use and Ocular Adnexal Features
Shah M, Lee G, Lefebvre DR, et al.
PLoS ONE
Cross-sectional survey (n=343) documenting periorbital adverse effects of topical prostaglandin analogs including 2.3-fold increased risk of dermatochalasis involution, 2.5-fold increased periorbital fat loss, and 4.0-fold increased upper lid ptosis — establishing the safety profile that drives regulatory scrutiny and demand for non-PG alternatives.
Regulatory & Market Context
EU SCCS Opinion SCCS/1680/25 on Prostaglandin Analogues in Cosmetics
SCCS concludes that prostaglandin analogues MDN, isopropyl cloprostenate, and DDDE cannot be considered safe in cosmetic products intended to promote eyelash/eyebrow growth. Cites reproductive/developmental toxicity data gaps.
Health Canada Cosmetic Ingredient Hotlist — Prostaglandins
Prostaglandins, their salts, derivatives and analogues are listed as prohibited in cosmetic products in Canada, creating market demand for non-prostaglandin alternatives.
FDA Cosmetic Classification Guidance
Claims to “restore hair growth” or “treat hair loss” are restricted medical claims under US FDA guidance. Cosmetic claims must focus on appearance (e.g., “fuller-looking hair”). MoCRA (2022) adds oversight but does not change the claim boundary.
See How Teams Use These Products
Evaluation guides tailored to your industry — see which products fit your application, review key evidence, and request samples.
FAQ
Frequently Asked Questions
Common technical questions about this product line, answered by our scientific team.
Related Resources
Technical data, product specifications, and application guidance.